An additional oligosaccharide moiety in the HA of a pandemic influenza H1N1 candidate vaccine virus confers increased antigen yield in eggs

Vaccine

Volumn 30, Issue 4, 2012, Pages 745-751

  Nicolson, Carolyn ^a   Harvey, Ruth ^a   Johnson, Rachel ^a   Guilfoyle, Kate ^a   Engelhardt, Othmar G ^a   Robertson, James S ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

HA antigen yield; High growth reassortants; Influenza vaccine; Reverse genetics

Indexed keywords

AMINO ACID; ANTIGEN; ARGININE; HEMAGGLUTININ; INFLUENZA VACCINE; LYSINE; OLIGOSACCHARIDE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGENICITY; ARTICLE; CANDIDATE VACCINE VIRUS; CONTROLLED STUDY; EGG; GENETIC REASSORTMENT; GENETIC VARIABILITY; GLYCOSYLATION; INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; VIRAL GENETICS; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, VIRAL; CHICK EMBRYO; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; OLIGOSACCHARIDES;

EID: 84855341520     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.081     Document Type: Article

References (30)

1. Characteristics of the emergent influenza A (h1N1) and viruses and recommendations for vaccine development, [accessed 07.07.11]. http://www.who.int/csr/resources/publications/swineflu/H1N1Vaccinevirusrecommendation26May2009.pdf.
2. World now at the start of 2009 influenza pandemic, [accessed 07.07.11]. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
3. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 1969, 41:643-645.
4. Kilbourne E.D., Schulman J.L., Schild G.C., Schloer G., Swanson J., Bucher D. Correlated studies of a recombinant influenza virus vaccine, I. Derivation and characterisation of the virus and vaccine. J Infect Dis 1971, 124:449-462.
5. Robertson J.S., Nicolson C., Harvey R., Johnson R., Major D., Guilfoyle K., et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011, 29:1836-1843.
6. Nicolson C., Major D., Wood J.M., Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, 23:2943-2952.
7. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory based influenza surveillance. U.S. Department of Health and Human Services, (Centers for Disease Control, Atlanta); 1982.
8. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
9. Hsu J.C. Multiple comparisons, theory and methods 1996, Chapman and Hall.
10. Harvey R., Wheeler J.X., Wallis C.L., Robertson J.S., Engelhardt O.G. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008, 26:6550-6554.
11. Wood J.M., Schild G.C., Newman R.M., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for the potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5:237-247.
12. Harvey R., Nicolson C., Johnson R.E., Guilfoyle K.A., Major D.L., Robertson J.S., et al. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine 2010, 28:8008-8014.
13. Gambaryan A.S., Tuzikov A.B., Psikarev V.E., Yamnikova S.S., Lvov D.K., Robertson J.S., et al. Specification of receptor binding phenotypes of influenza virus isolated from different hosts using synthetic sialylglycopolymers: non-egg adapted human H1 and H3 influenza A and influenza B share common high binding affinity for 6'-Sialyl(N-acetyllactosomine). Virology 1997, 232:345-350.
14. Aytay S., Schulze I. Single amino acid substitutions in the haemagglutinin can alter the host range and receptor binding properties of H1 strains of influenza virus. J Virol 1991, 65:3022-3028.
15. Ilyushina N.A., Khalenkov A.M., Seiler J.P., Forrest H.L., Bovin N.V., Marjuki H., et al. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 2010, 84:8607-8616.
16. Chen Z., Wang W., Zhou H., Suguitan A., Shamburgh C., Kim L., et al. Generation of live attenuated novel influenza Virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84:44-51.
17. Roger Sayle, James Milner-White E. RasMol: biomolecular graphics for all. Trends Biochem Sci (TIBS) 1995, 20(September (9)):374.
18. Farnsworth A., Cyr T.D., Li C., Wang J., Li X. Antigenic Stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 2010, 29:1529-1533.
19. Ohuchi R., Ohuchi M., Garten W., Klenk H-D. Oligosaccharides in the stem region maintain influenza virus haemagglutinin in the metastable form required for fusion activity. J Virol 1997, 71:3719-3725.
20. Mitnaul L.J., Mastrosovich M.N., Castrucci M.R., Tuzikov A.B., Bovin N.V., Kobasa D., et al. Balanced hamagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 2000, 74:6015-6020.
21. Wagner R., Mastrosovich M., Klenk H-D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002, 12:159-166.
22. Lu B., Zhou H., Ye D., Kemble G., Jin H. Improvement of Influenza A/Fujian/411/02 (h3N2) virus growth in embryonated chicken eggs by balancing the haemagglutinin and neuraminidase activities using reverse genetics. J Virol 2005, 79:6763-6771.
23. Wagner R., Wolff T., Herwig A., Pleschka S., Klenk H-D. Interdependence of haemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol 2000, 74:6316-6323.
24. Banks J., Plowright L. Additional glycosylation at the receptor binding site of the haemagglutinin (HA) for H5 and H7 viruses may be adaptation to poultry hosts, but does it influence pathogenicity. Avian Dis 2003, 47:942-950.
25. Robertson J.S. Clinical influenza virus and the embryonated hen's egg. Rev Med Virol 1993, 3:97-106.
26. Phyala R., Ikonen N., Haanpaa M., Kinnunen L. HA1 domain of influenza A (H3N2) viruses in Finland in 1989-1995: Evolution, egg adaptation and relationship to vaccine strains. Arch Virol 1996, 141:1033-1046.
27. Gambaryan A.S., Robertson J.S., Matrosovich M.N. Effects of egg-adaptation on the receptor binding properties of human influenza A and B viruses. Virology 1999, 258:232-239.
28. Robertson J.S., Nicolson C., Bootman J.S., Major D., Robertson E.W., Wood J.M. Sequence analysis of the haemagglutinin (HA) of influenza A H1N1 viruses present in clinical material and comparison with the HA of laboratory derived virus. J Gen Virol 1991, 72:2671-2677.
29. Barr I.G., Komadina N., Lee R.T., Lin R.T., Deng Y., Caldwell N., et al. A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. EuroSurveill 2010, 15(42). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19692 [accessed 07.07.11].
30. Suphaphiphat P., Franti M., Hekele A., Lilja A., Spencer T., Settembre E., et al. Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs. Virol J 2010, 7:157-161.